Next Article in Journal
MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
Previous Article in Journal
Exogenous and Endogenous Dendritic Cell-Derived Exosomes: Lessons Learned for Immunotherapy and Disease Pathogenesis
 
 
Review

Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies

1
The American University of Antigua-College of Medicine, Coolidge 1451, Antigua and Barbuda
2
Laboratory of Pharmaceutics, NanoBioCel Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
3
Histology and Cell Biology Department, Faculty of Medicine, University of Alexandria, Alexandria 21561, Egypt
*
Authors to whom correspondence should be addressed.
Academic Editor: Alexander E. Kalyuzhny
Cells 2022, 11(1), 116; https://doi.org/10.3390/cells11010116
Received: 10 November 2021 / Revised: 8 December 2021 / Accepted: 14 December 2021 / Published: 30 December 2021
Glioblastoma (GB), an aggressive primary tumor of the central nervous system, represents about 60% of all adult primary brain tumors. It is notorious for its extremely low (~5%) 5-year survival rate which signals the unsatisfactory results of the standard protocol for GB therapy. This issue has become, over time, the impetus for the discipline of bringing novel therapeutics to the surface and challenging them so they can be improved. The cell-based approach in treating GB found its way to clinical trials thanks to a marvelous number of preclinical studies that probed various types of cells aiming to combat GB and increase the survival rate. In this review, we aimed to summarize and discuss the up-to-date preclinical studies that utilized stem cells or immune cells to treat GB. Likewise, we tried to summarize the most recent clinical trials using both cell categories to treat or prevent recurrence of GB in patients. As with any other therapeutics, cell-based therapy in GB is still hampered by many drawbacks. Therefore, we highlighted several novel techniques, such as the use of biomaterials, scaffolds, nanoparticles, or cells in the 3D context that may depict a promising future when combined with the cell-based approach. View Full-Text
Keywords: glioma; stem cell; CAR-T cell; immune cell therapy; cell therapy; cancer glioma; stem cell; CAR-T cell; immune cell therapy; cell therapy; cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Attia, N.; Mashal, M.; Pemminati, S.; Omole, A.; Edmondson, C.; Jones, W.; Priyadarshini, P.; Mughal, T.; Aziz, P.; Zenick, B.; Perez, A.; Lacken, M. Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies. Cells 2022, 11, 116. https://doi.org/10.3390/cells11010116

AMA Style

Attia N, Mashal M, Pemminati S, Omole A, Edmondson C, Jones W, Priyadarshini P, Mughal T, Aziz P, Zenick B, Perez A, Lacken M. Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies. Cells. 2022; 11(1):116. https://doi.org/10.3390/cells11010116

Chicago/Turabian Style

Attia, Noha, Mohamed Mashal, Sudhakar Pemminati, Adekunle Omole, Carolyn Edmondson, Will Jones, Priyanka Priyadarshini, Temoria Mughal, Pauline Aziz, Blesing Zenick, Ambar Perez, and Morgan Lacken. 2022. "Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies" Cells 11, no. 1: 116. https://doi.org/10.3390/cells11010116

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop